Condition: Dermatomyositis · Sponsor: The Cleveland Clinic
This study will assess the safety and efficacy of topical ruxolitinib for treating the refractory cutaneous manifestations in patients with dermatomyositis. The investigators' hypothesis is that topical ruxolitinib will be both safe and effective for such patients.
This description comes directly from the study's public registry record.
Anthony Fernandez, MD · 216 445-8776 · dermatologyresearch@ccf.org
Rothy Rim · 2164447277 · dermatologyresearch@ccf.org
Always discuss trial participation with your own doctor first.
| Cleveland Clinic | Cleveland, Ohio, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06857240